Rocket Pharmaceuticals (RCKT) Cash from Financing Activities (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Cash from Financing Activities data on file, last reported at -$1000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to -$1000.0; the trailing twelve-month figure through Mar 2026 stood at $147000.0 (down 99.92% YoY), and the FY2025 full-year result was $148000.0, down 99.92% from the prior year.
• Cash from Financing Activities rose to -$1000.0 in Q1 2026, from -$67000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $189.5 million in Q3 2023 to a low of -$67000.0 in Q3 2025.
• A 5-year average of $36.6 million and a median of $1.2 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities surged 46664.45% in 2024 and tumbled 138.07% in 2025, its largest moves.
• Tracing RCKT's Cash from Financing Activities over 5 years: stood at $108.4 million in 2022, then plunged by 99.64% to $391000.0 in 2023, then surged by 46664.45% to $182.8 million in 2024, then sank by 100.04% to -$67000.0 in 2025, then soared by 98.51% to -$1000.0 in 2026.
• Business Quant data shows RCKT's Cash from Financing Activities at -$1000.0 in Q1 2026, -$67000.0 in Q3 2025, and $215000.0 in Q2 2025.